揚農化工(600486.SH)預計半年度實現營業總收入95.65億元、同比增長43%
格隆匯7月21日丨揚農化工(600486.SH)公佈,經公司初步核算,2022年1-6月,公司實現營業總收入95.65億元左右,同比增長43%左右;實現歸屬於上市公司股東的淨利潤15.14億元左右,同比增長91%左右。
2022年1-6月營業收入、歸屬於上市公司股東的淨利潤增長,主要原因一是部分主要農藥產品價格較上年同期上漲,二是公司子公司江蘇優嘉植物保護有限公司三期項目全面達產,四期項目第一階段項目相繼投產,公司積極應對上半年疫情不利影響,保持產銷順暢,促進了經營業績大幅提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.